Data / Research funding / Washington / Benaroya Research Inst at Virginia Mason
Benaroya Research Inst at Virginia Mason: 56 NIH awards ($278.6M), fiscal years 2021 to 2026
Benaroya Research Inst at Virginia Mason in Seattle, WA is funded under 56 NIH awards ($278.6M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- PK9FMGRDRVD5
- State
- Washington
Awards
56 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Immune Tolerance Network | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $203,912,588 | February 1, 2014 | January 31, 2028 | BUCKNER, JANE HOYT | reporter.nih.gov |
| Systems Immunology profiling of respiratory viral infections in vulnerable populations | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,440,069 | March 29, 2022 | February 28, 2027 | MIKACENIC, CARMEN R | reporter.nih.gov |
| Type 1 Diabetes TrialNet Clinical Network Hub | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,959,999 | September 9, 2014 | May 31, 2030 | GREENBAUM, CARLA J | reporter.nih.gov |
| Harnessing engineered T regulatory cells to promote beta cell health in T1D | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,920,533 | April 8, 2022 | January 31, 2026 | BUCKNER, JANE HOYT | reporter.nih.gov |
| Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy | NIH | National Cancer Institute | 2021 to 2024 | $3,284,686 | September 1, 2019 | August 31, 2025 | BUCKNER, JANE HOYT | reporter.nih.gov |
| Unmodified and Post Translationally Modified CD4+ and CD8+ T cell Epitopes in Rheumatoid Arthritis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,237,408 | September 30, 2019 | September 29, 2023 | BENTON, RYAN | reporter.nih.gov |
| Mechanistic and functional dissection of inflammaging in Down syndrome | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,165,277 | September 1, 2022 | August 31, 2027 | KHOR, BERNARD | reporter.nih.gov |
| Proteomic analysis of hydroxychloroquine prevention trials in T1D, RA and SLE | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $2,978,715 | August 18, 2023 | July 31, 2028 | BUCKNER, JANE HOYT | reporter.nih.gov |
| Commensal-specific T cell function in skin wound repair | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,918,975 | February 1, 2021 | April 30, 2026 | HARRISON, OLIVER JAMES | reporter.nih.gov |
| Allergen T cell epitopes and phenotypes in peanut allergy and immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,851,788 | January 1, 2018 | December 31, 2023 | KWOK, WILLIAM W. | reporter.nih.gov |
| BCAP regulation of TLR7/9 signaling in Lupus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,809,161 | December 1, 2019 | November 30, 2025 | HAMERMAN, JESSICA A | reporter.nih.gov |
| Clonal expansion: a marker of disease activity in stage 1 T1D | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $2,532,731 | July 15, 2024 | June 30, 2027 | LONG, S ALICE | reporter.nih.gov |
| Immune Checkpoints in Acute Respiratory Distress Syndrome (IC-ARDS) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,270,999 | September 5, 2020 | June 30, 2026 | MIKACENIC, CARMEN R | reporter.nih.gov |
| Defining mechanisms of CD8 T cell exhaustion in T1D | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,256,570 | April 10, 2020 | March 31, 2026 | LONG, S ALICE | reporter.nih.gov |
| Investigating monocyte dysfunction in Down Syndrome | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $2,109,849 | July 24, 2019 | December 31, 2024 | HAMERMAN, JESSICA A | reporter.nih.gov |
| Reprogramming of tissue structural cells by cutaneous CD4+ T cells | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,900,303 | April 19, 2023 | March 31, 2028 | CAMPBELL, DANIEL J | reporter.nih.gov |
| Regulatory T cells maintain immune homeostasis through translation control | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,719,847 | December 13, 2023 | October 31, 2028 | ZIEGLER, STEVEN F | reporter.nih.gov |
| Plasmacytoid dendritic cells and IgA autoantibodies in SLE | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,707,941 | June 12, 2024 | April 30, 2029 | HAMERMAN, JESSICA A | reporter.nih.gov |
| LITAF regulation of membrane repair and inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,671,416 | July 1, 2024 | May 31, 2029 | LACY-HULBERT, ADAM | reporter.nih.gov |
| Investigating Genetic and Epigenetic Control of T Cell Function in Autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $1,559,700 | September 8, 2023 | August 31, 2026 | RAY, JOHN PHILIP | reporter.nih.gov |
| Regulation of Intestinal Immunity and Repair by Integrins | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,486,099 | June 17, 2024 | April 30, 2028 | LACY-HULBERT, ADAM | reporter.nih.gov |
| Type 1 Diabetes in Acute Pancreatitis Consortium – Pacific Northwest Clinical Center: Immune Pathogenesis of Post-Pancreatitis T1D | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,379,600 | September 16, 2020 | July 31, 2030 | SPEAKE, CATE | reporter.nih.gov |
| Targeting the IL-2/regulatory T cell axis for autoimmune disease prevention in realistic animal models | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,358,528 | December 20, 2017 | November 30, 2023 | CAMPBELL, DANIEL J | reporter.nih.gov |
| Build to LEAD - Building partnerships to Link the Exposome to Autoimmune Disease (Administrative Supplement) | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,279,936 | August 18, 2025 | August 31, 2026 | BUCKNER, JANE HOYT | reporter.nih.gov |
| Genetic variants guiding pathogenicity of colitogenic T cells | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,007,304 | September 1, 2024 | June 30, 2027 | RAY, JOHN PHILIP | reporter.nih.gov |
| Foxp3 isoform expression and regulation of autoantibody production | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $709,019 | November 19, 2024 | October 31, 2029 | ZIEGLER, STEVEN F | reporter.nih.gov |
| Specialization and targeting of CD4+ tissue resident memory T cells in EAE | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $687,422 | July 22, 2025 | June 30, 2030 | BETTELLI, ESTELLE | reporter.nih.gov |
| Regulation of cutaneous immunity and tissue-repair by a specialized population of CD4+ T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $485,684 | June 20, 2017 | November 30, 2022 | CAMPBELL, DANIEL J | reporter.nih.gov |
| Foxp3DEx2 isoform expression leads to Treg dysfunction and SLE | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $478,775 | March 3, 2021 | August 31, 2023 | ZIEGLER, STEVEN F | reporter.nih.gov |
| Control of CD8+ T cell migration and activation by Flightless-1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $478,775 | March 5, 2021 | February 28, 2023 | CAMPBELL, DANIEL J | reporter.nih.gov |
| Autoreactive CD4 Tscm Development in Type 1 Diabetes | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $476,575 | August 9, 2022 | January 31, 2025 | CEROSALETTI, KAREN M | reporter.nih.gov |
| Mechanisms of Il-2-mediated immune tolerance | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $476,575 | August 18, 2023 | July 31, 2025 | CAMPBELL, DANIEL J | reporter.nih.gov |
| Regulation of TLR signaling in anti-commensal B cell responses and mucosal inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $476,575 | April 19, 2023 | March 31, 2025 | LACY-HULBERT, ADAM | reporter.nih.gov |
| Identifying autoimmune associated genes in patrolling monocytes that promote lupus nephritis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $476,575 | July 1, 2023 | December 31, 2025 | HAMERMAN, JESSICA A | reporter.nih.gov |
| Foxp3 isoforms and IgE-mediated UVB-induced skin inflammation expression | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $476,575 | May 22, 2023 | April 30, 2025 | ZIEGLER, STEVEN F | reporter.nih.gov |
| T Cell Epigenomic Drivers of Disease Flares in Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $476,575 | June 1, 2024 | April 30, 2027 | BUCKNER, JANE HOYT | reporter.nih.gov |
| T cell-mediated control of dermal fibroblast gene programs and dysfunction in scleroderma | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $476,575 | June 12, 2024 | April 30, 2027 | MORAWSKI, PETER A | reporter.nih.gov |
| Prioritizing autoimmune-associated genetic variants that alter regulatory element activity in B cells | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $476,276 | April 15, 2022 | March 31, 2025 | RAY, JOHN PHILIP | reporter.nih.gov |
| Development and functions of tissue resident memory T cells during EAE | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $476,076 | February 1, 2022 | April 30, 2024 | BETTELLI, ESTELLE | reporter.nih.gov |
| Regulation of Tfh function in autoimmunity by TSLP | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $476,076 | February 1, 2022 | January 31, 2024 | ZIEGLER, STEVEN F | reporter.nih.gov |
| Characterization of E. coli-specific T cells in Crohn's disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $476,075 | February 1, 2022 | January 31, 2024 | LORD, JAMES DANIEL | reporter.nih.gov |
| DCs as clinical targets of anti-integrin therapy in IBD | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $470,076 | December 1, 2023 | October 31, 2026 | LORD, JAMES DANIEL | reporter.nih.gov |
| Modulation of pathogenic T cells in EAE | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $470,076 | November 13, 2023 | October 31, 2025 | BETTELLI, ESTELLE | reporter.nih.gov |
| Regulation of pathogenic T cells in EAE | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $428,750 | December 1, 2016 | November 30, 2022 | BETTELLI, ESTELLE | reporter.nih.gov |
| LITAF regulation of cell death and inflammatory responses | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $299,631 | August 10, 2023 | June 30, 2024 | LACY-HULBERT, ADAM | reporter.nih.gov |
| Evaluating the role of high-dose influenza vaccine in people with Down syndrome under age 65 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $286,793 | September 24, 2025 | August 31, 2026 | SPEAKE, CATE | reporter.nih.gov |
| Prioritizing and Characterizing T Cell-Relevant Genetic Variants Associated with Autoimmune Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $270,000 | December 18, 2020 | November 30, 2022 | RAY, JOHN PHILIP | reporter.nih.gov |
| Characterizing circulating and visceral T cells specific for the autoantigen integrin αvβ6 in ulcerative colitis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $252,152 | December 4, 2024 | November 30, 2026 | LORD, JAMES DANIEL | reporter.nih.gov |
| IgA-containing immune complexes in plasmacytoid dendritic cell activation in SLE | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $217,625 | May 22, 2020 | April 30, 2022 | HAMERMAN, JESSICA A | reporter.nih.gov |
| Mechanisms of suppression of effector T cells in EAE | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $213,875 | January 21, 2020 | December 31, 2022 | BETTELLI, ESTELLE | reporter.nih.gov |
| alpha v integrin regulation of B cell tolerance | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $200,000 | December 16, 2020 | November 30, 2021 | LACY-HULBERT, ADAM | reporter.nih.gov |
| Illuminating a novel role of understudied DYRKs in anti-inflammatory T cell differentiation | NIH | National Center for Advancing Translational Sciences | 2021 | $174,100 | May 1, 2021 | April 30, 2023 | KHOR, BERNARD | reporter.nih.gov |
| Using B cell features to explain heterogeneity in the rate of T1D progression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $174,100 | September 15, 2020 | August 31, 2024 | SPEAKE, CATE | reporter.nih.gov |
| Regulation of germinal centers by thymic stromal lymphopoietin in mice and humans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $140,296 | July 1, 2020 | June 30, 2023 | DOMEIER, PHILLIP P | reporter.nih.gov |
| Inflammation-associated anemia and the role of monocyte-derived inflammatory hemophagocytes in a model of blood-stage malaria | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $140,296 | August 1, 2020 | July 31, 2023 | OROZCO, SUSANA LUCIA | reporter.nih.gov |
| Building tools to study commensal-specific CD8+ T cells in the small intestine | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $86,650 | April 1, 2025 | March 31, 2027 | HARRISON, OLIVER JAMES | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 24 | $48,389,112 | 0 | $0 |
| 2024 | 27 | $55,161,839 | 0 | $0 |
| 2023 | 27 | $56,657,139 | 0 | $0 |
| 2022 | 25 | $47,450,760 | 0 | $0 |
| 2021 | 23 | $70,965,795 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 40 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 40 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 40 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 40 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 40 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 40 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 40 awards here |
Topics of its NIH awards
- Autoimmune Disease
- Clinical Research
- Genetics
- Brain Disorders
- Lupus
- Immunotherapy
- Prevention
- Pediatric
- Human Genome
- Infectious Diseases
- Diabetes
- Multiple Sclerosis
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.